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Abstract
Background: Prevalence and risk factors for respiratory symptoms and airway obstruction in HIV-infected subjects in the era
of highly active antiretroviral therapy (HAART) are unknown. We evaluated respiratory symptoms and measured airway
obstruction to identify the impact of HAART and other risk factors on respiratory symptoms and pulmonary function.
Methodology/Principal Findings: Two hundred thirty-four HIV-infected adults without acute respiratory symptoms were
recruited from an HIV clinic. All subjects were interviewed and performed spirometry. Multivariate linear and logistic
regressions were performed to determine predictors of respiratory symptoms, forced expiratory volume in one second
(FEV1) percent predicted, and FEV1/forced vital capacity (FEV1/FVC). Thirty-one percent of subjects reported at least one
respiratory symptom. Smoking status (current or former versus never) (odds ratio [OR] = 2.7, 95% confidence interval
[CI] = 1.41–5.22, p = 0.003), higher log plasma HIV viral levels (OR= 1.12, 95%CI = 1.02–1.24, p = 0.02), and lower FEV1/FVC
(OR= 1.06 for every 0.01 decrease in FEV1/FVC, 95%CI = 1.02–1.14, p = 0.001) were independent predictors of respiratory
symptoms. Age (p = 0.04), pack-year smoking history (p,0.001), previous bacterial pneumonia (p = 0.007), and HAART use
(p = 0.04) were independent predictors of decreased FEV1/FVC.
Conclusions/Significance: Respiratory symptoms remain common in HIV-infected subjects, especially in those with a
smoking history. Subjects who were older, had a greater pack-year history of smoking, or previous bacterial pneumonia had
lower FEV1/FVC ratios. Interestingly, use of HAART was independently associated with a decreased FEV1/FVC, possibly
secondary to an immune response to subclinical infections, increased autoimmunity, or other factors associated with HAART
use.
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Introduction
The development of highly active antiretroviral therapy
(HAART) has led to impressive declines in morbidity and mortality
from the human immunodeficiency virus (HIV) [1]. With decreases
in opportunistic infections and malignancies, a new constellation of
conditions has emerged that have been linked to antiretroviral
medications or to extended periods of time living with HIV. In
particular, conditions such as cardiovascular disease, dyslipidemia,
insulin resistance, and osteoporosis seem to be accelerated in HIV-
infected persons receiving HAART [2,3]. Immune reconstitution
inflammatory syndrome (IRIS) has also been reported in HIV-
infected persons initiating HAART who develop inflammatory
reactions to either known or occult pathogens, and autoimmune
disease has been seen during immune restoration [4,5].
In the pre-HAART era, HIV-infected persons had a high
prevalence of respiratory complaints including cough, shortness of
breath, and dyspnea on exertion [6], and HIV infection had been
associated with accelerated development of emphysema, airway
obstruction, and reduced diffusing capacity for carbon monoxide
[7,8]. Respiratory complaints occurred even in individuals without
a history of AIDS or pulmonary infections. Although one study
examined chronic obstructive pulmonary disease (COPD) as
documented by self-report and ICD-9 diagnoses in HIV-infected
patients in the HAART era, no studies have measured airway
obstruction directly [9]. Therefore, the impact of HAART on
frequency of respiratory symptoms or airway obstruction is
unknown.
Risk factors for respiratory symptoms and airway obstruction
reported in the pre-HAART era might also have changed with
HAART. Most previous studies documented an association
between smoking, respiratory symptoms, and airway obstruction
among HIV-infected individuals [6,10]. Other pre-HAART era
risk factors for respiratory symptoms included intravenous drug
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use (IDU), low CD4 cell count, and previous pneumonia [6]. Pre-
HAART risk factors for airway obstruction included IDU,
previous Pneumocystis pneumonia (PCP), and previous bacterial
pneumonia [8,11]. It is important to determine current risk factors
for respiratory complaints and airflow obstruction in order to
identify and treat affected patients.
We conducted a cross-sectional study of HIV-infected individ-
uals presenting to an HIV clinic for routine care. Our overall aims
were to investigate the frequency of respiratory symptoms and
airway obstruction during the HAART era, identify risk factors,
and explore the relationship of HAART to symptoms and airway
obstruction. We report the first prospective study to directly
measure pulmonary function in HIV-infected individuals in the




Our objectives were to determine frequency of respiratory
symptoms and airway obstruction during the HAART era, to
identify associated risk factors, and to determine the relationship of
HAART to symptoms and pulmonary function.
Participants
Subjects were HIV-infected adult outpatients at the University
of Southern California HIV clinic, who were enrolled between
September 2003 and September 2004. Subjects who had new or
increasing cough, shortness of breath, or fever in the past four
weeks were excluded, as were subjects with self-reported asthma.
Description of Investigations Undertaken
Data collection. Data were collected by subject interview
and standardized medical record abstraction using pre-determined
definitions. Information collected from subjects included age,
gender, race and ethnicity, HIV risk factor, medication use,
smoking history, and history of an AIDS-defining diagnosis.
History of pneumonia was obtained from both patient interview
and chart review. HAART was defined as use of at least three
medications from two classes of antiretroviral drugs within the
previous 3 months as determined by medical record review.
Current smokers were defined as those smoking at least one
cigarette each day and at least a lifetime total of 100 cigarettes.
Former smokers had quit for greater than one year. Subjects were
asked about presence or absence of chronic respiratory symptoms
including cough, shortness of breath, and dyspnea on exertion.
Laboratory values for CD4 cell counts and plasma HIV viral levels
were obtained within six months of spirometry testing.
Spirometry. All subjects performed spirometry according to
American Thoracic Society guidelines [12]. Predicted values were
calculated using published reference values [13].
Ethics
The University of Southern California Institutional Review
Board approved the study. All subjects gave written informed
consent.
Statistical Methods
Statistical analysis. Data were double-entered to ensure
accuracy. Stata 8 (Stata Corporation, College Park, TX) was used
for analysis, and significance determined for a p-value #0.05.
Variables were described using either t-tests and Wilcoxon rank-
sum, or chi-square and Fisher’s exact.
Percentage of subjects reporting respiratory symptoms was
determined for individual symptoms and for any symptom.
Univariate analyses were performed to determine clinical variables
related to reporting any respiratory symptom. Step-wise forward
and backward multivariate logistic regression was performed to
determine independent predictors of respiratory symptoms by
including variables significant at a level of p#0.1 in univariate
analyses. If two variables were significantly correlated (i.e.,
smoking status and pack-year history), the variable with the
strongest univariate relationship to the outcome was included.
Interactions of variables were explored. Model fit was assessed
using the Hosmer-Lemeshow goodness-of-fit test [14].
Forced expiratory volume in one second (FEV1) percent
predicted, forced vital capacity (FVC) percent predicted, and
FEV1/FVC were described for the entire cohort. The percentages
of subjects with airway obstruction as determined both by FEV1/
FVC below the 5% lower limit of normal adjusted for age and
FEV1/FVC less than 0.70 were calculated [12]. Subjects with
airway obstruction were also categorized according to the Global
Initiative on Chronic Obstructive Lung Disease (GOLD) staging
[15]. Univariate analyses were performed to determine variables
associated with FEV1 percent predicted and FEV1/FVC. Stepwise
forward and backward multivariate linear regression was per-
formed to determine independent predictors of FEV1/FVC by
including variables at a level of p#0.1 in univariate analyses. The
strongest univariate predictor was included in the multivariate
model if two variables were significantly correlated. CD4 cell
counts and plasma HIV viral levels were missing for 13 subjects.
We compared models with and without subjects with missing data,
and there were no significant differences. Data on HAART use
were missing or incomplete (i.e. subjects reported recent use of
fewer than 3 medications) in 19 subjects. Models were run without
subjects who lacked adequate information on HAART use. For
subjects reporting use of less than three antiretrovirals, we ran
models including them in the HAART group and excluding them
as well. There were no significant differences between these two
models and because we felt the data were less reliable in the
subjects reporting non-standard ART regimens, we chose to
exclude them in the final model. We explored interactions
between model variables. Because we were specifically interested
in the relationship of HAART to FEV1/FVC, we investigated
other potential interactions and modifying effects for relationship
of HAART use to FEV1/FVC. To account for confounding, we
explored potential mediators and moderators, such as plasma HIV
viral levels, CD4 cell counts, and smoking history, using linear




Two hundred and thirty-four subjects participated. The
majority (82.5%) were men (Table 1). Subjects ranged in age
from 26 years to 70 years, with a mean age of 44.1 years. There
was a high prevalence of smoking as 59.8% were either current or
former smokers. Among smokers, the median number of pack-
years was 10. The median CD4 cell count in the cohort was
371 cells/ml and the majority (83.3%) of subjects were receiving
HAART. HAART users were more likely to be male (odds ratio
[OR] = 4.16, 95% confidence interval [CI] = 1.56-11.11, p = 0.007)
and less likely to be current or former smokers (OR = 0.32,
95%CI = 0.08–0.92, p = 0.004) (Table 2). Subjects on HAART had
lower log plasma HIV viral levels (6.4 copies/ml vs. 8.0 copies/ml,
p = 0.02), but lower CD4 cell counts (333 cells/ml vs. 554 cells/ml,
HAART and Airway Obstruction
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p = 0.002). There was no significant difference in time HIV-infected
between HAART users and those not using HAART (8 years vs. 10
years, p = 0.6).
Respiratory symptoms
Prevalence of any respiratory symptom was 31.5%. Cough was
most frequently reported, occurring in 23.0% of subjects. Sixteen
percent of subjects reported dyspnea on exertion and 3.0%
complained of shortness of breath at rest. Current or former
smokers were more symptomatic than never smokers (Figure 1).
Age, intravenous drug use, smoking history, higher log plasma
HIV viral levels and a history of bacterial pneumonia were
associated with a higher likelihood of reporting respiratory
symptoms (Table 1). There were no differences in FEV1 percent
predicted of those with and without symptoms, but FEV1/FVC
was significantly lower among symptomatic subjects. Multivariate
analysis demonstrated that current or former smoking status
(OR = 2.7, 95% CI = 1.41–5.22, p = 0.003), higher log serum HIV
viral levels (OR = 1.12, 95% CI = 1.02–1.24, p = 0.02), and lower
FEV1/FVC (OR = 1.06, 95% CI = 1.02–1.14, p = 0.001) were
independent predictors of respiratory symptoms.
Spirometry
Most subjects (93.2%) had normal spirometry. Mean FEV1 was
99.1 percent of predicted. Mean FVC was 94.0 percent of
predicted, and mean FEV1/FVC was 0.82. The prevalence of
clinical obstruction as determined by the 5% lower limit of age-
adjusted normal was 8.6% and by the FEV1/FVC below 0.70 was
6.8%. Of these subjects, 62.5% were classified as GOLD stage I,
and 37.5% were GOLD stage II.
No characteristics were significantly associated with FEV1
including age, gender, race/ethnicity, HIV risk factor, smoking
or pack-year history, CD4 cell count or HIV viral level, use of
HAART, or history of pneumonia. In contrast, several clinical
characteristics were associated with a lower FEV1/FVC (Table 3).
The ratio decreased with increasing age (p,0.001) and those who
were Hispanic had a higher FEV1/FVC than other racial groups
(0.81 versus 0.79, p = 0.01). Subjects who were current or former
Table 1. Characteristics of HIV-infected subjects according to respiratory symptoms.
Characteristic Entire cohort No symptoms Symptoms P OR (95% CI)
n =234 n=161 n=73
Age, mean years (SD) 44.1 (9.4) 43.1 (9.9) 46.4 (8.0) 0.002 1.04 (1.01–1.07)*
Gender
Male, n (%) 193 (82.5) 134 (83.2) 59 (80.8) 0.65
Female, n (%) 41 (17.5) 27 (16.8) 14 (19.2)
Race/ethnicity
White, n (%) 32 (13.7) 18 (11.2) 14 (19.2) 0.40
African-American, n (%) 66 (28.2) 43 (26.7) 23 (31.5)
Hispanic, n (%) 124 (53.0) 92 (57.1) 32 (43.8)
Other, n (%) 12 (5.1) 8 (5.0) 4 (5.5)
HIV risk factor (n = 223)
MSM, n (%) 107 (48.0) 74 (49.0) 33 (45.8) 0.93
IDU, n (%) 27 (12.1) 14 (9.3) 13 (18.1) 0.04 2.30 (1.01–5.13)
Heterosexual, n (%) 89 (39.9) 63 (41.7) 26 (36.1) 0.61
Smoking history"
Current, n (%) 87 (37.1) 51 (31.7) 36 (49.3) 0.0003 3.45 (1.64–7.14)
Former, n (%) 53 (22.6) 32 (19.9) 21 (28.8) ,0.001 4.76 (2.13–10.00)
Never, n (%) 94 (40.2) 78 (48.4) 16 (21.9)
Pack-year history, median years, (range) 1.1 (0–90) 0.5 (0–90) 4.5 (0–60) 0.04 1.02 (1.001–1.05)*
CD4 cell count, median cells/ml (range) 371 (3–1368) 380 (14–1010) 313 (3–1368) 0.86
Log plasma HIV viral level, mean copies/ml (SD) 6.5 (2.8) 6.2 (2.7) 7.2 (3.1) 0.02 1.12 (1.02–1.24)
History of AIDS, n (%) 150 (64.1) 102 (63.4) 48 (65.8) 0.72
Use of HAART, n (%) 195 (83.3) 133 (82.6) 62 (84.9) 0.86
History of PCP, n (%) 37 (15.8) 25 (15.5) 12 (16.4) 0.86
History of BP, n (%) 64 (27.4) 37 (23.0) 27 (37.0) 0.02 2.01 (1.10–3.67)
Hepatitis C, n (%) 29 (12.4) 16 (9.9) 13 (17.8) 0.09
FEV1 percent predicted, mean (SD) 99.1 (15.7) 100.0 (15.2) 96.9 (16.6) 0.15
FEV1/FVC, mean (SD) 0.82 (0.07) 0.81 (0.07) 0.78 (0.07) 0.001 1.06 (1.02–1.14)ˆ
Note: BP = bacterial pneumonia; CI = confidence interval; HAART =highly active antiretroviral therapy; IDU = intravenous drug use; MSM=men who have sex with men;
OR =odds ratio; PCP = Pneumocystis pneumonia; SD = standard deviation.
*per year.
ˆper 0.01 decrease.
"Odds ratio as compared to never smokers.
doi:10.1371/journal.pone.0006328.t001
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smokers had a lower FEV1/FVC than never smokers (0.79 versus
0.82, p = 0.01) and FEV1/FVC decreased with increasing pack-
year history (p,0.001). Subjects with a history of hepatitis C had a
lower ratio than those who did not (0.77 versus 0.81, p = 0.02), as
did those who reported a history of bacterial pneumonia (0.78
versus 0.81, p = 0.001). There was a trend for subjects receiving
HAART to have a lower FEV1/FVC (0.80 versus 0.83, p = 0.09).
Multivariate modeling demonstrated that older age (p = 0.04),
pack-year history of smoking (p,0.001), and history of bacterial
pneumonia (p = 0.007) were independent predictors of lower
FEV1/FVC (Table 3). Use of HAART was also an independent
predictor of a lower FEV1/FVC (p = 0.04). There were no
significant interactions among variables in the model and no
significant mediators or modifiers responsible for the effect of
HAART. Sixteen subjects (8.2%) receiving HAART met clinical
criteria for airway obstruction (FEV1/FVC,0.70), but none of the
subjects not receiving HAART had clinical obstruction (p = 0.37).
There were no relationships of FEV1/FVC to particular classes of
antiretroviral therapy, although we were unable to assess
nucleoside reverse transcriptase inhibitors (NRTI) separately from
HAART as virtually all subjects receiving HAART were using an
NRTI.
Discussion
This study is the first to prospectively examine respiratory
symptoms and directly measure spirometry in the HIV-infected
population in the era of HAART. It is also the first study to report
an association between HAART use and airway obstruction.
Respiratory symptoms remain common in the current era and are
Table 2. Characteristics of HIV-infected subjects according to use of HAART.
Characteristic HAART (n=195) Non-HAART (n=20) P
Age, mean years (SD) 44.4 (9.3) 42.0 (11.0) 0.28
Gender
Male, n (%) 168 (86.2) 12 (60.0) 0.007
Female, n (%) 27 (13.9) 8 (40.0)
Race/ethnicity
White, n (%) 28 (14.4) 3 (15.0) 0.03
African-American, n (%) 54 (27.7) 11 (55.0)
Hispanic, n (%) 106 (54.4) 5 (25.0)
Other, n (%) 7 (3.6) 1 (5.0)
HIV risk factor (n = 187)
MSM, n (%) 74 (44.3) 6 (30.0) 0.77
IDU, n (%) 22 (13.2) 3 (15.0)
Heterosexual, n (%) 71 (42.5) 11 (55.0)
Smoking history
Current, n (%) 65 (33.3) 14 (70.0) 0.004
Former, n (%) 45 (2.3) 2 (10.0)
Never, n (%) 85 (43.6) 4 (20.0)
Pack-year history, median years (range) 0.55 (0–90) 10 (0–37) 0.04
CD4 cell count, median cells/mL (range) 333 (3–1076) 554 (124–1368) 0.002
Log plasma HIV viral level, mean copies/mL (SD) 6.4 (2.9) 8.0 (2.6) 0.02
History of AIDS, n (%) 137 (70.2) 2 (10.0) ,0.001
History of PCP, n (%) 29 (14.9) 1 (5.0) 0.32
History of BP, n (%) 53 (27.2) 8 (40.0) 0.30
Hepatitis C, n (%) 23 (11.8) 4 (20.0) 0.29
Time HIV-infected, median years (range) 8 (1–24) 10 (1–21) 0.60
Note: BP = bacterial pneumonia; CI = confidence interval; HAART =highly active antiretroviral therapy; IDU = intravenous drug use; MSM=men who have sex with men;
OR =odds ratio; PCP = Pneumocystis pneumonia; SD = standard deviation.
doi:10.1371/journal.pone.0006328.t002
Figure 1. Prevalence of respiratory symptoms in HIV-infected
subjects according to smoking history. Current/former smokers
shown in black, never smokers in white. Dyspnea = dyspnea on
exertion, shortness of breath = shortness of breath at rest. *p = 0.001;
{p=0.01; {p,0.001.
doi:10.1371/journal.pone.0006328.g001
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associated with age, smoking history, lower FEV1/FVC, and
higher HIV viral levels. We found that a lower FEV1/FVC ratio is
independently related to age, pack-year smoking history, and
history of bacterial pneumonia. Interestingly, we also discovered
an independent relationship of HAART use with lower FEV1/
FVC.
Previous studies documented a high prevalence of respiratory
symptoms in the pre-HAART era [6,17]. Diaz found that
approximately 42% of 327 HIV-infected individuals reported
dyspnea and 40% reported cough [6]. In the current cohort, only
16% complained of dyspnea and 23% of cough. Overall, about
one-third of our subjects had respiratory symptoms. Although it is
difficult to compare cohorts, respiratory symptoms may be
somewhat less prevalent than previous, although still fairly
common. Risk factors for respiratory symptoms were similar in
both studies. Diaz reported that cigarette smoking, IDU, low CD4
cell count, and previous history of pneumonia were associated with
increased respiratory symptoms. Similarly, we found that smoking
was the strongest predictor of respiratory symptoms and that age,
IDU, and history of bacterial pneumonia were associated with
increased respiratory symptoms. We did not find that CD4 cell
count was associated with respiratory symptoms, but high plasma
HIV viral levels were. Also, subjects with respiratory symptoms
had lower FEV1/FVC values than those not reporting symptoms,
suggesting that symptoms might be the result of airway
obstruction. Combined, these studies argue for increased efforts
at smoking cessation, substance abuse intervention, and routine
influenza and pneumococcal vaccinations in an effort to decrease
respiratory symptoms in HIV-infected patients.
Many studies from the pre-HAART era demonstrated that HIV is
associated with airway obstruction, emphysema, and decreased
diffusing capacity for carbon monoxide [7,8,11,18]. We found that
clinical airway obstruction was present in 6.8 percent of subjects;
however, given the different cohorts in these various studies, it is
challenging to make direct pre-HAART and post-HAART prevalence
comparisons. A recent study of HIV-infected veterans in the HAART
era reported that approximately 10 percent carried a diagnosis of
COPD based on ICD-9 codes [19], but direct measurements of
spirometry have not previously been performed in subjects receiving
HAART. Risk factors for decreased FEV1/FVC in our cohort were
generally consistent with pre-HAART risk factors and included age,
smoking pack-year history, and prior bacterial pneumonia [7,11].
Although a history of PCP has also been associated with obstruction
[11], we did not find this relationship, possibly secondary to lack of
power or inaccuracy in diagnosis of PCP.
Most notably, we found that HAART use was associated with a
decreased FEV1/FVC after controlling for other independent risk
factors such as age, cigarette smoking, intravenous drug use, and
previous pneumonia. Although absolute differences in FEV1/FVC
were small in subjects receiving HAART, these subjects were young
and face a lifetime of antiretroviral treatment. Therefore, they may
be at risk of developing clinically significant disease as they age.
Airway obstruction may be the latest in a series of chronic
conditions linked to HAART. Prolonged HIV infection and
HAART have been associated with cardiovascular disease,
metabolic syndrome, osteoporosis, rheumatologic disorders, and
thyroid disease [20,21]. The mechanistic link between HAART
and airway obstruction is not known, but potential explanations
include direct effects of HAART in the lung, restoration of the
immune system allowing for renewed response to subclinical
infections, and/or the development of autoimmunity.
HAART-associated cardiovascular disease, metabolic syn-
drome, and osteoporosis may be directly related to particular
antiretroviral agents, particularly protease inhibitors [22,23], but
there are no published reports of HAART medications linked to
airway obstruction. We did not see a statistically significant
association between protease inhibitors and obstruction, but we
might have lacked sufficient power to detect this relationship.
Further research is warranted to investigate the direct pulmonary
effects of HAART.
HAART might also potentiate airway obstruction through indirect
mechanisms such as aberrant immune restoration. IRIS is a well-
documented side-effect of HAART initiation that occurs in response
to known or occult pathogens [4]. Individuals placed on HAART
may experience symptoms such as fever, worsening lung infiltrates,
and lymphadenopathy [4,24]. These symptoms likely result from
release of memory CD4+ T-cells occurring weeks to months after
HAART initiation. We propose that there may be a ‘‘modified’’ IRIS
that, while not resulting in overt respiratory disease, stimulates
pulmonary inflammation in response to occult or colonizing
pathogens and subsequently results in airway obstruction.
In the non-HIV-infected population, the vicious circle hypoth-
esis has been proposed as one mechanism leading to COPD [25].
This theory postulates that continued inflammation in response to
microorganisms perpetuates lung damage and COPD. Bacterial
pathogens such as Streptococcus pneumonia and Haemophilus influenzae,
and viral pathogens such as adenovirus, have been implicated in
COPD pathogenesis [26,27]. Pneumocystis jirovecii colonization has
also been linked to COPD in the non-HIV-infected population
and has been found using polymerase chain reaction in as many as
70 percent of HIV-infected individuals without acute Pneumocystis
pneumonia [28,29]. One of these organisms or HIV itself could
act, with a persistent, but low organism burden, as a nidus of
chronic inflammation in the context of improved immune function
after starting HAART.
Another possible explanation of the association of HAART and
airway obstruction, which does not necessarily exclude a role for
infections, is that an autoimmune response develops after initiating
HAART. Organ-specific autoimmunity has been demonstrated as
a complication of HAART and occurs later than infection-
associated IRIS [5,30]. Conditions such as autoimmune thyroid
disease, sarcoidosis, autoimmune hepatitis, and arthritis have been
noted after beginning HAART [20,21,30,31,32]. Detectable anti-
thyroid antibodies appear after HAART initiation, and clinical
Table 3. Predictors of airway obstruction in HIV-infected
subjects.
Univariate predictors Coefficient P
Age 20.18 ,0.001
Hispanic ethnicity (versus non-Hispanic) 2.3 0.01
Smoking history (former/current versus never) 22.2 0.01
Smoking pack-year history 20.19 ,0.001
Hepatitis C 23.2 0.02
History of bacteria pneumonia 23.2 0.001
Use of HAART 22.8 0.09
Multivariate predictors
Age 20.10 0.04
Smoking pack-year history 20.15 ,0.001
History of bacterial pneumonia 22.8 0.007
Use of HAART 23.2 0.04
Note: HAART = highly active antiretroviral therapy.
doi:10.1371/journal.pone.0006328.t003
HAART and Airway Obstruction
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6328
thyroid disease is associated with a lower pre-HAART CD4 cell
count [20,21]. The proposed mechanism of autoimmunity during
immune restoration involves release of naı¨ve T-cells and generally
occurs more than six months after HAART initiation. Autoreac-
tive T-cells are subsequently more likely to be activated in the
setting of infections, thymic dysfunction, or altered cytokine
profiles associated with HIV infection and HAART [20,33,34,35].
It has also been postulated that production of T-regulatory cells is
impaired in HIV-infected subjects during HAART and might lead
to decreased ability to suppress autoimmunity [20,36]. Others
have shown that numbers of mucosal T-regulatory cells decrease
with HAART initiation [37], and it is possible that similar changes
occur in the lungs resulting in decreased ability to suppress the
autoimmune response.
Autoimmunity, either in response to infectious agents or other
triggers, has been linked to COPD in the non-HIV-infected population
[38,39,40]. Agusti proposed that an acquired immune response to self-
epitopes was an important contributor to the inflammation and
pulmonary damage seen in COPD [38]. Recent studies have shown
that non-HIV-infected COPD patients have increased anti-elastin and
anti-epithelial antibodies [39,40]. The susceptibility of HIV-infected
patients on HAART to developing autoimmunity in the setting of
immune restoration, combined with the findings supporting an
autoimmune pathogenesis in COPD, indicate that autoimmune
mechanisms may also be involved in HIV-related COPD.
Limitations
There are several limitations of our study. First, it was a cross-
sectional observational study of HIV-infected individuals; thus
limiting our ability to determine causation. Use of chart review for
assessing certain clinical variables is also difficult. We were unable
to assess effects of HAART on progression of airway obstruction
or to determine effects of length of HAART use, HAART
compliance, or nadir CD4 cell count, as this information was not
reliably available. Use of plasma HIV viral levels as surrogate
markers of adherence is also difficult, but HAART users did have
lower HIV viral levels than those not receiving HAART,
suggesting that at least some subjects were compliant with
HAART. It also did not appear that length of HIV infection
was associated with airway obstruction, but this information is
difficult to obtain accurately. In addition, pulmonary testing was
limited to pre-bronchodilator spirometry. Subjects with a history
of asthma were excluded, but we cannot rule out the possibility
that some subjects had asthma. Airway hyperresponsiveness was
previously reported in HIV-infected subjects, although not at a
significantly higher prevalence than in controls and it was more
common in those with a self-reported history of asthma, a group
excluded from our study [41]. We were not able to examine the
association of HAART and diffusing capacity for carbon
monoxide or anatomic emphysema as demonstrated on computed
tomography. Thus, we might have underestimated the association
of HAART and pulmonary disease. Nonetheless, the finding that
HAART is associated with airway obstruction is important
whether it represents asthma or COPD, and future studies are
needed to determine the exact phenotype associated with HIV and
HAART use. Finally, there might be unmeasured variables
associated with HAART use and airway obstruction that were
not considered in our model; however, we included most
previously reported variables associated with obstruction and, in
fact, HAART users were actually less likely to smoke, yet had
more obstruction.
As this study was performed at a single center, results may not
be able to be generalized to all populations of HIV-infected
patients. Subjects were from an urban area, and populations in
different settings or different geographic locations might not be
similar to the one reported here. Inclusion of relatively healthy
subjects who attended an outpatient clinic may have also biased
results in finding a lower prevalence of respiratory symptoms and
pulmonary function deficits than would be found in a cohort with
more advanced disease or in those who do not seek primary care.
This study is the first prospective examination of airway
obstruction and risk factors in HIV-infected persons during the
HAART era. While most risk factors for airway obstruction were
similar to those seen in the pre-HAART era, we found a novel,
independent association of HAART and airway obstruction.
Although the effect of HAART was small, the subjects in our study
were young and the mild changes identified here could become
clinically important over a lifetime of antiretroviral therapy.
Future studies are needed to improve understanding of the
relationship of HAART and pulmonary abnormalities, to
determine progression of abnormalities over time, and to discover
the mechanism of this association in order to provide treatment or
prevention.
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